富途资讯6月22日消息，本周二The new stock knocks on the blackboard:
Guitong Tongqiao-B will issue 60 million shares at a price of HK $39.8-HK $42.70 each with a minimum subscription amount of HK $21565.15 on June 22-25 and is expected to list on July 5.
Guichuan Tongqiao is a leader in China's neural and peripheral vascular intervention medical device market, and the IPO has received a total of US $145 million subscribed by cornerstone investors such as Hillhouse, Fidelity International and Qingchi Capital.
Futu News, June 22, this Tuesday.Guichuangtong Bridge-B (02190.HK) $According to the announcement, the company plans to issue 60 million shares from June 22 to 25, including 6 million shares for public offering and 54 million shares for international offering at a price of HK $39.8 to HK $42.70 per share.
Guicuang Tongqiao is a market leader in neurovascular interventional medical devices in China. Currently, the company's treatment areas include acute ischemic stroke (AIS), intracranial aneurysms, carotid artery stenosis, peripheral arterial and venous diseases and dialysis-related diseases.
According to Frost Sullivan, the company provides patients and doctors with one of China's domestic neurovascular medical device companies.The most comprehensiveCovers a portfolio of solutions for neurological and peripheral vascular interventional medical devices. The company's current neurovascular product portfolio covers a full range of five categories (namely, ischemia, hemorrhage, stenosis, carotid artery, vascular pathway device), and Guichuangtong Bridge is China.The only one in the countryCompanies have been developed covering all five categories of neurovascular product portfolios mentioned above.
In terms of financial data, the company's revenue in 2019 and 2020 was 4.917 million yuan and 27.631 million yuan respectively, while the company recorded a net loss of 66.647 million yuan and 100 million yuan in the same period. According to the prospectus, with advancing preclinical research, continuing the clinical development of candidate products and seeking regulatory approval, launching products under development, and expanding the commercialization of approved products in China and overseas, the company is expected to incur more operating expenses in the near future.
In terms of industry, the size of China's neural interventional medical device market has increased from 2.6 billion yuan in 2015 to 4.9 billion yuan in 2019, with a compound annual growth rate of 17.3%. It is expected to further increase to 37.1 billion yuan by 2030, with an annual compound growth rate of 20.2% from 2019 to 2030.
According to Frost Sullivan, among the Chinese medical device companies, Guichuang Tongqiao Medical Co., Ltd. has obtained the most CE marks for nerve and peripheral vascular interventional medical devices. As of the last practical date, Guichuang Tongqiao Medical has obtained the CE marks of 8 products and commercialized 4 products in Europe.
In terms of product coverage and product quantity of disease ╱, the overall competition pattern of domestic companies in China's neural and peripheral vascular interventional device market.
As for cornerstone investors, a number of cornerstone investors agreed to subscribe for the number of offering shares available for subscription at the offering price, totaling about US $145 million, includingHillhouse Capital, Fidelity International, Qingchi Capital, Boyu Capital, AIHC Master Fund, Hudson Bay, Snow Lake Capital, Cormorant, Octagon, Athos Capital, Sage Partners and Ivy Capital.
In terms of fund-raising purposes, the company intends to use the net proceeds from the share sale for the following purposes: about 37% will be allocated to core products (i.e. Jiaolong intracranial thrombectomy stent and Ultrafree DCB); about 11% will be allocated to the continuous R & D, production and commercialization of other five major products; and about 40% will be allocated to other 38 products and pipelines in order to develop a product portfolio to provide a full range of solutions. About 3% will be allocated for further upgrading of R & D facilities; about 4% will be allocated for potential strategic acquisitions, investments, authorized introduction or cooperation; and about 5% will be used for working capital and general corporate purposes.
Edit / Aurora
